TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11570629

Group type: EXPERIMENTAL
Intervention: Therapeutic electrical stimulation (TES) applied to antagonists of spastic leg muscles
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no TES)
Number of subjects: 12
Study: 9592914

Group type: EXPERIMENTAL
Intervention: Patelladyn-bandage
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Kasseler-bandage
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Super-Genuplus-bandage
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Genuhit-bandage
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bandages (all types)
Number of subjects: 25
Study: 8166188

Group type: EXPERIMENTAL
Intervention: 2% clindamycin vaginal cream
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Persistent or recurrent sialidase 8 weeks after treatment
Number of subjects: 271
Study: 3285312

Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dietary changes (hydrolyzed casein formula or elimination of milk from mothers' diets)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Counseling after reexposure to cow's milk or soy protein
Number of subjects: 20
Study: 31194584

Group type: EXPERIMENTAL
Intervention: Color of tether adjuster casing (black or red)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Labeling on tether adjuster casing (labeled with 'Tether: Use for forward‐facing' or unlabeled)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Storage location of tether (bundled in a rubber band on the back of CRS or Velcroed over the forward‐facing belt path)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Labeling in vehicle (labeled under head restraint and below anchor or unlabeled)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Installation using lower anchors (LAs)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Overall installation methods (including seat belt use)
Number of subjects: 96
Study: 27838659

Group type: EXPERIMENTAL
Intervention: Health advice and text messaging (SMSalud®)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Health advice (control group)
Number of subjects: 320
Study: 25988461

Group type: EXPERIMENTAL
Intervention: Oral prednisone (tapering 15-day course: 60 mg for 5 days, 40 mg for 5 days, 20 mg for 5 days; total cumulative dose = 600 mg; n=181)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Oral prednisone (n=181)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo (n=88)
Number of subjects: 269
Study: 23394461

Group type: EXPERIMENTAL
Intervention: Never smokers
Number of subjects: 29367

Group type: EXPERIMENTAL
Intervention: Current light smokers (<15 pack-years)
Number of subjects: 29367

Group type: EXPERIMENTAL
Intervention: Unemployed/retired subjects
Number of subjects: 29367

Group type: COMPARATOR
Intervention: Current smoking
Number of subjects: 29367

Group type: EXPERIMENTAL
Intervention: Unemployment/premature retirement
Number of subjects: 29367

Group type: EXPERIMENTAL
Intervention: Asthma
Number of subjects: 29367

Group type: EXPERIMENTAL
Intervention: Allergic rhinitis
Number of subjects: 29367

Group type: EXPERIMENTAL
Intervention: Current heavy smoking (≥15 pack-years)
Number of subjects: 29367
Study: 21426607

Group type: EXPERIMENTAL
Intervention: Fermented pre-term formula
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard pre-term formula
Number of subjects: 58
Study: 19466959

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1%-BPO 2.5% fixed-dose combination gel
Number of subjects: 1670

Group type: COMPARATOR
Intervention: Adapalene 0.1% monotherapy
Number of subjects: 1670

Group type: COMPARATOR
Intervention: BPO 2.5% monotherapy
Number of subjects: 1670

Group type: COMPARATOR
Intervention: Vehicle (gel vehicle)
Number of subjects: 1670

Group type: EXPERIMENTAL
Intervention: Adapalene-BPO
Number of subjects: 1670
Study: 16506874

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 4479

Group type: EXPERIMENTAL
Intervention: Physical therapy (subgroup with greatest propensity)
Number of subjects: 4479

Group type: COMPARATOR
Intervention: No physical therapy (control group)
Number of subjects: 4479
Study: 15541156

Group type: EXPERIMENTAL
Intervention: Computer-administered oral health questionnaire
Number of subjects: 453

Group type: COMPARATOR
Intervention: Face-to-face interview by research officer or dentist
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Order of questionnaire administration
Number of subjects: 453
Study: 11903420

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9577377

Group type: EXPERIMENTAL
Intervention: Amplification Refractory Mutation System (ARMS) test
Number of subjects: 46
Study: 7944471

Group type: EXPERIMENTAL
Intervention: OK-432
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: CDDP
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control
Number of subjects: 53
Study: 3588562

Group type: EXPERIMENTAL
Intervention: Experimental group (dietary counseling to restrict sodium intake)
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 1001
Study: 28840750

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) 10 mg by intra-articular injection
Number of subjects: 56

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) 25 mg by intra-articular injection
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) and Hyaluronic acid (HA)
Number of subjects: 56
Study: 27917921

Group type: EXPERIMENTAL
Intervention: Eye movement data recorded during ECG interpretation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Permutation test comparing gaze shifts
Number of subjects: 31
Study: 24850106

Group type: EXPERIMENTAL
Intervention: Concordant provocation during interlaminar epidural steroid injection
Number of subjects: 48

Group type: COMPARATOR
Intervention: Discordant provocation during interlaminar epidural steroid injection
Number of subjects: 48
Study: 24359174

Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors (SRIs) - clomipramine and paroxetine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 20966692

Group type: EXPERIMENTAL
Intervention: Postplacental IUD insertion
Number of subjects: 102

Group type: COMPARATOR
Intervention: Delayed IUD insertion
Number of subjects: 102
Study: 18626126

Group type: EXPERIMENTAL
Intervention: Individualized brochure (IB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: General brochure (GB)
Number of subjects: 100
Study: 12131867

Group type: EXPERIMENTAL
Intervention: Pidotimod (400 mg x 2 daily for 15 days, then 400 mg daily for 20 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pidotimod
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 9690761

Group type: EXPERIMENTAL
Intervention: Conventional ribotyping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulsed field gel electrophoresis (PFGE) assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCR‐ribotyping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis of RFLP data
Number of subjects: 0
Study: 8024131

Group type: EXPERIMENTAL
Intervention: Cooling rate of 0.7 ± 0.1 degrees C/h
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cooling rate of 1.7 ± 0.4 degrees C/h
Number of subjects: 16
Study: 2685958

Group type: EXPERIMENTAL
Intervention: Fish oil (MaxEPA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (olive and corn oil)
Number of subjects: 40
Study: 949899

Group type: EXPERIMENTAL
Intervention: Clemastine 1 mg b.d. for 3 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 28556062

Group type: EXPERIMENTAL
Intervention: Probiotic combination (Lactobacillus plantarum, Lactobacillus brevis, Pediococcus acidilactici), 2 oral tablets per day for 6 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (same tablets without live bacteria), 2 oral tablets per day for 6 weeks
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Probiotic combination
Number of subjects: 59
Study: 26846042

Group type: EXPERIMENTAL
Intervention: Colgate ProClinical A1500 Power Toothbrush
Number of subjects: 79

Group type: COMPARATOR
Intervention: Manual flat-trim toothbrush (Oral-B Indicator)
Number of subjects: 79
Study: 22700844

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 7250

Group type: COMPARATOR
Intervention: Salmeterol
Number of subjects: 7250
Study: 21624729

Group type: EXPERIMENTAL
Intervention: In Our Own Voice intervention
Number of subjects: 156
Study: 19784509

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with 0.5% ropivacaine and PCA with 0.2% ropivacaine + fentanyl 3 microg.mL‐1
Number of subjects: 41

Group type: COMPARATOR
Intervention: Continuous lumbar plexus block with 0.5% ropivacaine and PCA with 0.2% ropivacaine
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 41

Group type: COMPARATOR
Intervention: Lumbar plexus block
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 41
Study: 16720930

Group type: EXPERIMENTAL
Intervention: Surgery followed by chemotherapy (CEOP-Bleo: cyclophosphamide, epirubicin, vincristine, prednisone, and bleomycin at standard doses)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 102
Study: 15567627

Group type: EXPERIMENTAL
Intervention: Complete intervention on A tests (arm I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete intervention on B tests (arm II)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm without any intervention on B tests (arm III)
Number of subjects: 0
Study: 11743058

Group type: EXPERIMENTAL
Intervention: Combined treatment (reducing sedentary behavior and increasing physical activity)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Increase intervention (increasing physical activity)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Adherence to treatment
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Predictors of targeted child weight loss
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Predictors of sibling weight loss
Number of subjects: 67
Study: 9449222

Group type: EXPERIMENTAL
Intervention: Ulcerative colitis nutritional formula (UCNF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 30
Study: 8498653

Group type: EXPERIMENTAL
Intervention: Perfusion flow rate of 2.4 L.min‐1 x m‐2 (Group I)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Perfusion flow rate of 1.2 L.min‐1 x m‐2 (Group II)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High perfusion flow (Group I)
Number of subjects: 20
Study: 31878131

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (14% CHO, 58% fat, 28% protein) for 4 weeks
Number of subjects: 19
Study: 29277060

Group type: EXPERIMENTAL
Intervention: SEMLS + PTS
Number of subjects: 22

Group type: COMPARATOR
Intervention: SEMLS no PTS
Number of subjects: 22
Study: 27551725

Group type: EXPERIMENTAL
Intervention: Monotherapy with darunavir/ritonavir (DRV/r‐MT arm)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Monotherapy with lopinavir/ritonavir (LPV/r‐MT arm)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard antiretroviral therapy (cART arm)
Number of subjects: 43
Study: 25367545

Group type: EXPERIMENTAL
Intervention: Electronic screening via tablet computer (with option for audio assist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face‐to‐face interview conducted by a fully bilingual/bicultural researcher
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electronic screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face‐to‐face screening
Number of subjects: 0
Study: 23212996

Group type: EXPERIMENTAL
Intervention: Healthier quintiles of modified Alternative Healthy Eating Index scores
Number of subjects: 31546

Group type: EXPERIMENTAL
Intervention: Healthier diet
Number of subjects: 31546
Study: 19763805

Group type: EXPERIMENTAL
Intervention: Dynamic facial expressions
Number of subjects: 13

Group type: COMPARATOR
Intervention: Static facial expressions
Number of subjects: 13
Study: 19097474

Group type: EXPERIMENTAL
Intervention: Finger movement before gait initiation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Finger movement after gait initiation
Number of subjects: 13

Group type: COMPARATOR
Intervention: No finger movement (gait initiation without finger movement)
Number of subjects: 13
Study: 17136691

Group type: EXPERIMENTAL
Intervention: Furosemide (60 mg) mixed with human albumin (HA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Furosemide (60 mg) mixed with fresh frozen plasma (FFP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 0
Study: 14572020

Group type: EXPERIMENTAL
Intervention: Community intervention trial
Number of subjects: 23125

Group type: EXPERIMENTAL
Intervention: Experimental condition
Number of subjects: 23125

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 23125
Study: 10799416

Group type: EXPERIMENTAL
Intervention: Calcium supplementation during pregnancy
Number of subjects: 5
Study: 15321272

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 0
Study: 8244521

Group type: EXPERIMENTAL
Intervention: Sodium citrate (0.7 mmol/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ammonium chloride (2.2 mmol/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2428885

Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide (CGRP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Histamine, prostaglandin (PG) E2, PGI2, substance P, vasoactive intestinal peptide (VIP)
Number of subjects: 0
Study: 30810347

Group type: EXPERIMENTAL
Intervention: DR/ER-MPH 20 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: DR/ER-MPH 100 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: DR/ER-MPH 100 mg with high-fat meal
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: DR/ER-MPH 100 mg sprinkled on applesauce
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: DR/ER-MPH
Number of subjects: 62

Group type: COMPARATOR
Intervention: IR MPH 20 mg
Number of subjects: 62
Study: 30337510

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (4 g/day for 72 postoperative hours)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 140
Study: 27039845

Group type: EXPERIMENTAL
Intervention: paclitaxel/carboplatin + pelareorep (Arm A)
Number of subjects: 73

Group type: COMPARATOR
Intervention: paclitaxel/carboplatin (Arm B)
Number of subjects: 73
Study: 25415108

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (0.5%) infusion at 2 ml/hour for 48 hours
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (saline infusion)
Number of subjects: 80
Study: 22536662

Group type: EXPERIMENTAL
Intervention: 25% H2O2 gel
Number of subjects: 15

Group type: COMPARATOR
Intervention: 15% H2O2 gel
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both concentrations of H2O2 gel with whitening lamp
Number of subjects: 15
Study: 20644331

Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg/day for 6 months
Number of subjects: 40
Study: 17914513

Group type: EXPERIMENTAL
Intervention: Monopolar dissection tonsillectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy
Number of subjects: 100
Study: 16044058

Group type: EXPERIMENTAL
Intervention: Prilocaine and felypressin (Citanest and Octapressin)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 12362927

Group type: EXPERIMENTAL
Intervention: Ivermectin 30 mg (three times a week)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ivermectin 60 mg (three times a week)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ivermectin 90 mg (single dose)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ivermectin 120 mg (single dose)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 9925837

Group type: EXPERIMENTAL
Intervention: Gastrointestinal (GI) priming for 10 days
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Bolus tube-feeding method
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Human milk feeding
Number of subjects: 171

Group type: COMPARATOR
Intervention: Continuous tube-feeding method
Number of subjects: 171

Group type: COMPARATOR
Intervention: GI priming
Number of subjects: 171
Study: 7751894

Group type: EXPERIMENTAL
Intervention: 18FDG
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 11C‐methionine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Polychemotherapy
Number of subjects: 16
Study: 2106735

Group type: EXPERIMENTAL
Intervention: multi‐dose blood cardioplegia (BCP)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: hypothermic ventricular fibrillation (HF)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: single‐dose Bretschneider's crystalloid cardioplegia (CCP)
Number of subjects: 37
Study: 398481

Group type: EXPERIMENTAL
Intervention: Cefaclor at a dose of 20 mg/kg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefaclor at identical dosages as phenoxymethyl penicillin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefaclor administered twice daily or thrice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 0
Study: 31549255

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 184/22 mcg or 92/22 mcg
Number of subjects: 775900

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 775900

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 775900
Study: 30826974

Group type: EXPERIMENTAL
Intervention: Training of Affect Recognition (TAR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 24
Study: 29714423

Group type: EXPERIMENTAL
Intervention: Yijingfang (half dose, bid) for 3 months
Number of subjects: 450

Group type: COMPARATOR
Intervention: Wuziyanzong Pills (9 g, bid) + L‐carnitine oral liquid (10 ml, bid) for 3 months
Number of subjects: 450
Study: 25469673

Group type: EXPERIMENTAL
Intervention: SIS.NET (System for Individualized Survivorship Care)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 102
Study: 22451455

Group type: COMPARATOR
Intervention: High Ligation and Stripping (HL/ST)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Endovenous Laser Ablation (EVLA)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Endovenous Laser Ablation with High Ligation (EVLA/HL)
Number of subjects: 449
Study: 21052638

Group type: EXPERIMENTAL
Intervention: PTH(1‐84) (100 μg daily, subcutaneous injection)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Strontium ranelate (2 g daily, oral)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: PTH(1‐84)
Number of subjects: 81
Study: 19278378

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 607

Group type: COMPARATOR
Intervention: Traditional analgesics
Number of subjects: 607

Group type: COMPARATOR
Intervention: TENS
Number of subjects: 607
Study: 16914234

Group type: EXPERIMENTAL
Intervention: Three doses of pediatric inactivated HA vaccine (Avaxim 80) at 2, 4, and 6 months of age (Group A)
Number of subjects: 131

Group type: COMPARATOR
Intervention: One dose of pediatric inactivated HA vaccine (Avaxim 80) at 6 months of age (Group B)
Number of subjects: 131
Study: 12874818

Group type: EXPERIMENTAL
Intervention: Double filtration plasmapheresis (DFP)
Number of subjects: 8
Study: 11203849

Group type: EXPERIMENTAL
Intervention: Fuji‐II glass‐ionomer cement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amalgambond Plus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Panavia‐21
Number of subjects: 0

Group type: COMPARATOR
Intervention: Copalite
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prepared cavity without restoration
Number of subjects: 0
Study: 9106107

Group type: EXPERIMENTAL
Intervention: High potassium supplementation (7.7 mmol/kg/day)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard potassium intake (4.7 mmol/kg/day)
Number of subjects: 99
Study: 1443738

Group type: EXPERIMENTAL
Intervention: Clonidine (0.3 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3001563

Group type: EXPERIMENTAL
Intervention: Synthetic ovine corticotropin releasing factor (oCRF) 25, 50, 100, 200 micrograms
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Human corticotropin releasing factor (hCRF) 50 and 100 micrograms
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 6
Study: 30806083

Group type: EXPERIMENTAL
Intervention: Ameloblastoma (AM)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Keratocystic odontogenic tumor (KCOT)
Number of subjects: 50
Study: 27401709

Group type: EXPERIMENTAL
Intervention: Complementary follow‐up visits with clinical examinations, focused chest sonography and protocol‐driven thoracentesis if applicable
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Thoracentesis in patients with pleural effusion
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard postoperative care
Number of subjects: 76
Study: 25860002

Group type: EXPERIMENTAL
Intervention: Routine BCG vaccination at birth
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed BCG vaccination at 14 weeks
Number of subjects: 0
Study: 24171880

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg three times a day for three months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21303633

Group type: EXPERIMENTAL
Intervention: Single nostril administration of 25 U insulin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Single nostril administration of 50 U insulin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Single nostril administration of 75 U insulin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dual nostril administration of 50 U insulin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dual nostril administration of 75 U insulin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dual nostril administration of 100 U insulin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Single nostril administration of 25 U insulin with placebo (CPE-215)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Single nostril administration of 25 U placebo (CPE-215)
Number of subjects: 8